OBJECTIVES :

Two of the most prevalent female genitourinary cancers are Ovarian and Endometrial Cancer. Despite recent innovations in immuno-oncology, cytotoxic platinum and taxane therapies remain a mainstay of standard treatment, and these diseases, once advanced, continue to represent significant unmet need^1,2. This study assesses recent changes in treatment patterns and health resource utilization in these two cancers.

METHODS :

Data was obtained from a nationally representative institutional claims set, from 1/1/2015 to 03/20/2019. Data was transformed into the OMOP Common Data Model, version 5. Analyses were conducted using the SHYFT Quantum V6.7.0 solution. Patients with metastatic disease were identified by ICD-9/10 and by presence of antineoplastic therapy. Line of therapy analysis was conducted to assess treatment patterns, including time on therapy (TTD, TTNT). Health utilization were assessed with respect to office visits, inpatient hospitalization and duration, procedures, and treatments.

RESULTS :

Despite increasing use of PARP-inhibitors and other targeted agents, platinum-based and taxane-based cytotoxic agents continue to play a significant role across lines of therapy in these cancers. Annual Inpatient hospitalizations were similar in both cancers, on the order of 11.9 visits, with 44% of patients averaging 1 day length-of-stay (LOS) per visit, 30% with 2-5 days LOS, and 26% with greater than 5 days LOS.

CONCLUSIONS :

Ovarian and Endometrial cancer continue to represent significant opportunities to improve patient care and reduce burden of disease. Next steps will include the replication of this study design in a European dataset to compare trends in treatment patterns and health resource utilization against those found in the US.